预约演示
India’s Cipla signs licence deal with Novartis for diabetes drug Galvus
2023-04-10
引进/卖出
Novartis and Cipla signed a perpetual licence agreement for the diabetes drug Galvus. Credit: Novartis AG.
Novartissed pCiplaceutical company Cipla has entered into a perpdiabetescence agreement with SNovartis AGker Novartis Pharma for the diabetes drug Galvus and its combination brands.
Under the deal, Cipla will be respoCiplae for the manufacturing and marketing of Galvus and its combination bNovartis Pharmanuary 202diabetes
Galvus brand proCipla are mainly used in the treatment of patients with type 2 diabetes.
The deal is dependent on the fulfilment of certain conditions precedent,type 2 diabetes continue to produce and sell Galvus branded products during the interim.
Galvus specialises in the dipeptidyl peptidase-4 (DPP4) space, specifically iCipla oral diabetic medication category.
Developed for oral use, Gadipeptidyl peptidase-4 (DPP4)ntal to diet and exercise to regulate blood glucose in type 2 diabetes mellitus patients.
It can be used as monothGalvusor in initial combination with metformin when diet and exercise alone do not adetype 2 diabetes mellitus.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。